Key result
AF is linked to higher NT-proBNP levels versus sinus rhythm in acute ischemic stroke.
Why the study?
The study aimed to assess NT-proBNP levels in acute ischemic stroke patients according to clinical and radiological features and investigate its relationship with short-term clinical outcomes.
Does serum NT-proBNP level correlate with stroke subtype and short-term prognosis in patients with acute ischemic stroke?
Cohort (n=131)
Does serum NT-proBNP level correlate with stroke subtype and short-term prognosis in patients with acute ischemic stroke?
Elevated NT-proBNP levels in acute ischemic stroke patients can help identify cardioembolic etiology and paroxysmal atrial fibrillation, and predict worse short-term functional outcomes.
Answers are grounded in this paper and cite their sources.
NT-proBNP elevation may aid AF identification in acute ischemic stroke; leaves open added prognostic value beyond current tools.
Background and Aims: We aimed to assess N-terminal pro brain-type natriuretic peptide (NT-proBNP) levels in acute ischemic stroke (AIS) patients according to clinical and radiological features and to investigate its relationship with short term clinical outcomes. Methods: In our study, 107 patients with AIS were evaluated prospectively. Of all, 56 patients had no evidence of atrial fibrillation (AF) (sinus rhythm [SR] group) (52.3%), 24 patients had paroxysmal AF (pAF group) (22.4%), and the other 27 patients had chronic AF (cAF group) (25.3%). Demographic datas, clinical characteristics, laboratory and radiological findings, CHA2DS2 -VASc scores, NIHSS (National Institute of Health Stroke Scale) and modified Rankin Scale (mRS) scores on admission and at the third month evaluations were recorded. Good functional outcome at 3 months was defined as modified Rankin score (mRS) 2 or less. According to the TOAST (Trial of Org 10172 in Acute StrokeTreatment) and OCSP (Oxfordshire Community Stroke Project) study, ischemic stroke subtyping was performed. Serum NT-proBNP levels were estimated in 107 stroke patients and 24 age- and sex-matched control subjects. Venous blood samples were obtained for serum NT-proBNP measurement within the first 48 hours of the patient group. Results: Mean age of the 107 AIS patients was 68 ± 15.22 years and 58.9% of them were women. Compared to controls, the SR, pAF and cAF groups had higher plasma NT-proBNP levels (P < 0.001) and also NT-proBNP values were significantly higher in the pAF and cAF group than SR groups (P < 0.001). NT-proBNP values were significantly higher in cardioembolic (CE) (n = 57) group than in large artery atherosclerosis (LAA) (n = 20) and small vessel disease (SVD) (n = 30) groups (P < 0.001). NT-proBNP levels of noncardioembolic SR (n = 49) (P = 0.080), LAA and SVD groups (P = 0.103) were higher than the control group but the difference was not statistically significant. There was a positive correlation between NT-proBNP level and third month mRS scores in CE group (r = 0.491). Conclusions: NT-proBNP will contribute to predict cardioembolic and pAF groups and estimate the prognosis.
No takes yet. Share an insight, caveat, or question.
Arslan et al. (2022) conducted a cohort in Acute ischemic stroke (n=131). Serum NT-proBNP measurement vs. Healthy controls and sinus rhythm group was evaluated on Serum NT-proBNP levels across clinical/radiological features and correlation with 3-month functional outcome (r = 0.491, p=<0.001). Serum NT-proBNP levels were higher in acute ischemic stroke patients with paroxysmal or chronic atrial fibrillation compared to those with sinus rhythm.
Synapse has enriched 10 related papers. Consider them for comparative context: